{
    "nct_id": "NCT04947501",
    "official_title": "N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma",
    "inclusion_criteria": "* Diagnosis of NB as defined by histopathology (confirmed by the MSK Department of Pathology), BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.\n* HR-NB, defined as MYCN-amplified stage 2/3/4/4S at any age and stage 4 in patients >18 months old.\n* No more than one prior cycle of chemotherapy.\n* Age <19 years old.\n* Signed informed consent indicating awareness of the investigational nature of this treatment.\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 19 Years",
    "exclusion_criteria": "* Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity â‰¥ grade 3.\n* Inability to comply with protocol requirements.\n* Pregnancy is not an issue because all patients will be pre-adolescents.",
    "miscellaneous_criteria": ""
}